PL3579857T3 - Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień - Google Patents
Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawieńInfo
- Publication number
- PL3579857T3 PL3579857T3 PL18703026.7T PL18703026T PL3579857T3 PL 3579857 T3 PL3579857 T3 PL 3579857T3 PL 18703026 T PL18703026 T PL 18703026T PL 3579857 T3 PL3579857 T3 PL 3579857T3
- Authority
- PL
- Poland
- Prior art keywords
- bleedings
- prophylaxis
- treatment
- blood coagulation
- coagulation factor
- Prior art date
Links
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 208000032843 Hemorrhage Diseases 0.000 title 1
- 208000034158 bleeding Diseases 0.000 title 1
- 231100000319 bleeding Toxicity 0.000 title 1
- 230000000740 bleeding effect Effects 0.000 title 1
- 239000003114 blood coagulation factor Substances 0.000 title 1
- 229940019700 blood coagulation factors Drugs 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21038—Coagulation factor XIIa (3.4.21.38)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17155420 | 2017-02-09 | ||
| PCT/EP2018/053240 WO2018146235A1 (en) | 2017-02-09 | 2018-02-09 | A blood coagulation factor replacement product for use in the treatment or prophyl of bleedings |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3579857T3 true PL3579857T3 (pl) | 2022-07-25 |
Family
ID=58016586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18703026.7T PL3579857T3 (pl) | 2017-02-09 | 2018-02-09 | Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210308228A1 (en) * | 2020-04-04 | 2021-10-07 | The Board Of Regents Of The University Of Texas System | Method for reducing the occurrence of thrombosis or thromboembolism |
| CN113929741A (zh) * | 2020-06-29 | 2022-01-14 | 首都医科大学 | 华法林-4-O-乙酰-Gly-Pro-Arg-Pro-AA1及其合成、活性和应用 |
| WO2026048976A1 (ja) * | 2024-08-30 | 2026-03-05 | Ｋｍバイオロジクス株式会社 | 血液凝固第ｘ因子を含む安定な医薬組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
| DE3101752A1 (de) | 1981-01-21 | 1982-08-26 | Behringwerke Ag, 3550 Marburg | "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen" |
| DE3336631A1 (de) * | 1983-10-08 | 1985-04-18 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x |
| DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
| SI0796623T1 (en) * | 1996-03-20 | 2005-10-31 | Baxter Aktiengesellschaft | Pharmaceutical preparation for the treatment of blood coagulation disorders |
| AT409334B (de) | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| CN100415093C (zh) | 2003-01-27 | 2008-09-03 | 哈维斯特技术公司 | 从抗凝全血生产的自体或同种促凝剂 |
| FR2946348B1 (fr) | 2009-06-05 | 2011-08-05 | Lab Francais Du Fractionnement | Procede de preparation d'une composition de complexe prothrombique a haut degre de purete |
| DK2624859T3 (en) | 2010-10-06 | 2017-06-06 | Medimmune Ltd | FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY |
| TWI653047B (zh) | 2014-03-14 | 2019-03-11 | 百特製藥公司 | 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物 |
| WO2016198351A1 (en) * | 2015-06-10 | 2016-12-15 | Evonik Röhm Gmbh | Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer |
-
2018
- 2018-02-09 SG SG10201912497WA patent/SG10201912497WA/en unknown
- 2018-02-09 KR KR1020197018871A patent/KR102658958B1/ko active Active
- 2018-02-09 WO PCT/EP2018/053240 patent/WO2018146235A1/en not_active Ceased
- 2018-02-09 DK DK18703026.7T patent/DK3579857T3/da active
- 2018-02-09 CN CN201880005539.2A patent/CN110114074B/zh active Active
- 2018-02-09 ES ES18703026T patent/ES2913934T3/es active Active
- 2018-02-09 PL PL18703026.7T patent/PL3579857T3/pl unknown
- 2018-02-09 AU AU2018217375A patent/AU2018217375B2/en active Active
- 2018-02-09 JP JP2019532137A patent/JP7227905B2/ja active Active
- 2018-02-09 BR BR112019012772A patent/BR112019012772A2/pt unknown
- 2018-02-09 CA CA3046406A patent/CA3046406C/en active Active
- 2018-02-09 EP EP18703026.7A patent/EP3579857B1/en active Active
- 2018-02-09 US US16/474,803 patent/US11744880B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018146235A1 (en) | 2018-08-16 |
| CN110114074B (zh) | 2024-05-28 |
| CN110114074A (zh) | 2019-08-09 |
| CA3046406C (en) | 2024-01-30 |
| KR20190111912A (ko) | 2019-10-02 |
| US20190351028A1 (en) | 2019-11-21 |
| AU2018217375B2 (en) | 2024-04-18 |
| BR112019012772A2 (pt) | 2019-12-10 |
| AU2018217375A1 (en) | 2019-06-27 |
| ES2913934T3 (es) | 2022-06-06 |
| KR102658958B1 (ko) | 2024-04-22 |
| JP2020506880A (ja) | 2020-03-05 |
| WO2018146235A8 (en) | 2019-05-09 |
| CA3046406A1 (en) | 2018-08-16 |
| DK3579857T3 (da) | 2022-06-07 |
| SG10201912497WA (en) | 2020-02-27 |
| EP3579857B1 (en) | 2022-04-06 |
| JP7227905B2 (ja) | 2023-02-22 |
| EP3579857A1 (en) | 2019-12-18 |
| US11744880B2 (en) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| ZA201700459B (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| HUE073569T2 (hu) | Vegyületek, azok sói és alkalmazásuk betegségek kezelésére | |
| PL3377637T3 (pl) | Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry | |
| AU201810686S (en) | Skin treatment article | |
| SI3676285T1 (sl) | Cepivo za uporabo pri profilaksi in/ali zdravljenju bolezni | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| AU201810689S (en) | Skin treatment article | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| AU201810683S (en) | Skin treatment article | |
| AU201810687S (en) | Skin treatment article | |
| IL251351B (en) | Preparations for use in the treatment and prevention of surgical infections | |
| PL3197290T3 (pl) | Pasza dla ryb i jej zastosowanie w profilaktyce i leczeniu zespołu krwotocznego smoltów (hss) u łososiowatych | |
| HUE051875T2 (hu) | Egyláncú oligonukleotidok bõrrendellenességek orvosi kezelésében történõ alkalmazásra | |
| SG10201912497WA (en) | A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings | |
| ZA201807692B (en) | New use of product for skin treatment | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| AU201810675S (en) | Skin treatment article | |
| IL264600B (en) | A knife for use in medical treatment | |
| IL248428B (en) | 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis | |
| GB201521442D0 (en) | Polytpeptides and analogues thereof for use in the treatment of diabetes and bone disorders | |
| GB201510642D0 (en) | Process and apparatus for sterilizing used hygiene products | |
| IL268265B (en) | 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment | |
| HK1248110A1 (en) | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |